Neutralizing human monoclonal antibodies to hepatitis A virus recovered by phage display  by Kim, Sang Jick et al.
www.elsevier.com/locate/yviro
Virology 318 (2004) 598–607Neutralizing human monoclonal antibodies to hepatitis A virus recovered
by phage display
Sang Jick Kim,a Myeong Hee Jang,a Jack T. Stapleton,b Sun Ok Yoon,a Keun-Soo Kim,c
Eun-Seok Jeon,d and Hyo Jeong Honga,*
aAntibody Engineering Research Unit, Korea Research Institute of Bioscience and Biotechnology, Taejon 305-600, South Korea
bDepartment of Internal Medicine, Helen C. Levitt Center for Viral Pathogenesis, The University of Iowa, Iowa City, IA 52242, USA
cAprogen, Inc., Korea Research Institute of Bioscience and Biotechnology, Taejon 305-600, South Korea
dDepartment of Internal Medicine, College of Medicine, Chungnam National University, Taejon 301-040, South KoreaReceived 11 April 2003; returned to author for revision 18 September 2003; accepted 9 October 2003Abstract
Four human monoclonal antibodies (MAbs) to hepatitis A virus (HAV) were isolated from a phage-displayed antibody library constructed
from the peripheral blood lymphocytes (PBLs) of HAV-immune donors. The four MAbs showed differences in their affinity: two (HA6,
HA9) of them were dominant after four rounds of panning, and showed higher affinity than the other two (HA1, HA12). All four MAbs
showed HAV-neutralizing activity in radioimmunofocus inhibition assay and their neutralizing activity was positively correlated with their
affinities. Analysis of their epitope specificity by cross-competition binding assays suggested that HA6 and HA9 recognize extensively
overlapping epitopes, which overlap with those of HA1 and HA12, although HA1 and HA12 recognize distinct epitopes. In addition,
competition assays with known neutralizing murine MAbs suggested that the epitopes of four human MAbs extensively overlap with those of
B5B3 and K34C8 which are distinct but reside within the single, immunodominant neutralization site on the HAV capsid. The human MAbs
(HA6 and HA9) with highest affinity may be useful in the immunoprophylaxis of HAV infection.
D 2003 Elsevier Inc. All rights reserved.Keywords: HAV; Neutralization epitope; Fab; Phage display; Human antibody libraryIntroduction
Hepatitis A virus (HAV), a member of the family
Picornaviridae, is the causative agent of hepatitis A in
humans (Francki et al., 1991). Unlike hepatitis B or hepatitis
C viruses, HAV is only associated with acute viral hepatitis,
and is transmitted by the fecal–oral route via contaminated
water and food (Jones et al., 1977; Mahoney et al., 1992).
HAVoccasionally causes small and large epidemics of acute
hepatitis (Stapleton, 1999). There appears to be only one
serotype and significant antigenic variation is not detected
among different HAV strains (Lemon and Binn, 1983). For
the prevention of HAV infection, inactivated virus vaccines
are currently used for active immunization, but pooled
human immune globulin (IG) is used for passive immuno-0042-6822/$ - see front matter D 2003 Elsevier Inc. All rights reserved.
doi:10.1016/j.virol.2003.10.014
* Corresponding author. Antibody Engineering Research Unit, Korea
Research Institute of Bioscience and Biotechnology, PO Box 115, Yuseong,
Taejon 305-600, South Korea. Fax: +82-42-860-4597.
E-mail address: hjhong@kribb.re.kr (H.J. Hong).prophylaxis, mainly for people at high risk of infection such
as travelers to areas where the virus is endemic (Pollock and
Reid, 1969). The administration of IG prevented HAV
infection, even when administered as late as 2 weeks after
exposure to the virus (Mosley et al., 1968). It is unlikely that
vaccines will prevent infection until three or more weeks
post infection (Werzberger et al., 1992). IG preparations,
however, have several limitations, including high cost,
variability in the anti-HAV antibody levels in different
batches, and a declining rate of anti-HAV antibodies among
the donor population (Winokur and Stapleton, 1992). Even
using vaccinated individuals as donors for IG, anti-HAV
levels would be lower because vaccinated with the inacti-
vated HAV vaccine have anti-HAV titers approximately 10-
to 50-fold lower than individuals naturally infected with
HAV (Stapleton, 1999). Accordingly, neutralizing human
monoclonal antibodies (MAbs) to HAV would be a good
alternative for the immunoprophylaxis of HAV infection.
The HAV particle is encapsidated in an icosahedral
structure formed by 60 copies of at least three viral
Fig. 1. Phage ELISA showing the enrichment of HAV-specific Fab-phages
during panning cycles. After each round of panning, the output phage was
amplified and applied to microtiter wells coated with BSA (n) or HAV (5).
Each microtiter well was coated with 200 ng of the antigen. Bound phages
were detected by horseradish peroxidase (HRP)-conjugated anti-M13
antibody.
Table 1
Selection of anti-HAV Fab clones after the fourth round of panning
ELISA
(positive/total)
BstNI
fingerprinting
(identical/total)
Selected
Fab
22/24 13/22 HA6
7/22 HA9
1/22 HA1
1/22 HA12
S.J. Kim et al. / Virology 318 (2004) 598–607 599structural proteins (VP1, VP2, and VP3). HAV morphogen-
esis requires several steps initiated by coming together of
the viral proteins to form promoters (sedimentation coeffi-
cient of 5S) (Anderson and Ross, 1990; Borovec and
Anderson, 1993; Coulepis et al., 1982). Five of these
promoters assemble into a pentamer (14S), and 12 pentam-
ers, in turn, form the viral empty capsid (70S). The final
infectious HAV particle containing the 7.5-kb single-strand-
ed genomic RNA has a sedimentation coefficient of 156S.
The assembly of the individual capsid proteins into the
virion structure was shown to generate a single, immunodo-
minant neutralization site in the antigenic structure of HAV,
which is conformational in nature (Hughes and Stanton,
1985; Stapleton and Lemon, 1987) and which comprises
amino acids from both VP1 and VP3 (Ping and Lemon,
1992; Ping et al., 1988). Epitope mapping of a panel of
murine MAbs against the neutralization antigenic site sug-
gested that both 14S and 70S particles elicit HAV-neutral-
izing antibodies in mice (Stapleton et al., 1993). However,
little is known about the mechanism by which antibodies
neutralize HAV.
Analysis of escape mutants selected against HAV-neu-
tralizing murine MAbs showed that there are closely spaced
multiple epitopes within the single immunodominant neu-
tralization site (Ping and Lemon, 1992; Stapleton and
Lemon, 1987). Twenty-two neutralizing murine MAbs were
characterized as belonging to one of five different compe-
tition profile groups (Ping and Lemon, 1992). Group A
MAbs almost completely blocked the binding of K34C8 but
did not reduce the binding of B5B3; group B MAbs had
significantly greater blocking activity against K34C8 than
B5B3; group C had roughly equal blocking activity against
both K34C8 and B5B3; group D had greater blocking
activity against B5B3 than K34C8; and group E MAbsblocked only B5B3 and not K34C8 (Ping and Lemon,
1992). Recently, the generation and characterization of four
neutralizing chimpanzee MAbs to HAV were reported
(Schofield et al., 2002). The study suggested that three of
the MAbs recognized overlapping epitopes, although the
fourth recognized a distinct epitope. In addition, the epito-
pes of chimpanzee MAbs overlapped with that of K34C8,
but not with B5B3. So far, several neutralizing human
MAbs have been reported but their epitope specificities
have not been characterized (Day et al., 1991; Lewis et
al., 1993).
Phage display of antibody libraries has provided a
powerful tool for the isolation of human MAbs to specific
antigens (Barbas et al., 1992; Burton et al., 1991; de Haard
et al., 1999; Hoogenboom and Winter, 1992; Marks et al.,
1991). Large repertoires of human antibody fragments can
be displayed on the surface of filamentous bacteriophage
particles, and monoclonal antibody fragments having de-
sired specificity can be isolated by panning against the
antigens of interest.
In this study, we generated four neutralizing human
MAbs to HAV by phage display of the antibody library
generated from the peripheral blood lymphocytes (PBLs) of
immune donors recovered from hepatitis A. In addition, the
neutralization epitopes are characterized.Results
Isolation of HAV-specific Fabs from phage antibody library
The cDNAs encoding the immunoglobulin (Ig) g1 Fd
and n light chains were synthesized from total RNA of the
PBLs of the HAV-immune donors and cloned into a phage
display vector to construct a combinatorial library of 3.9 
107 clones, as described in Materials and methods. The
phage-displayed Fab library was panned four times against
HAV. Analysis of the antigen-binding activities of the
pooled phages after each round of the panning indicated
that HAV-binding phage clones were almost selected after
the third round of panning (Fig. 1). Finally, 24 phage clones
after the fourth panning were selected, and the gene III
fragment was removed to produce soluble Fab. Analysis of
the antigen-binding activities of the 24 Fab clones by
ELISA revealed that 22 clones were positive in HAV
Fig. 2. Amino acid sequences of VH (A) and VL (B) of HAV-specific human MAbs.
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clones, their BstNI restriction patterns were compared. The
result suggested that they could be grouped into four
different clones (HA1, HA6, HA9, and HA12). HA6 and
HA9 clones, which represented 59% and 32% of the Fab
clones, respectively, were dominant, although only single
HA1 and HA12 clones were obtained (Table 1).
Sequence analysis of HAV-specific Fab clones
Sequence analysis of the heavy and light chain variable
regions of the four clones (HA1, HA6, HA9, and HA12)
showed that their heavy chain variable region (VH) sequen-
ces including complementarity determining regions (CDRs)
that directly interact with the epitope of antigen were
markedly different from each other (Fig. 2). They were
originated from different germline VH segments and also
had somatic hypermutations. In contrast, the light chain
variable region (VL) sequences were originated from DPK9
germline segment of human VK1 family and were highly
homologous to each other. Especially, the VL sequences of
the three clones (HA1, HA6, and HA9) were almost
identical to DPK9. The results of the sequence analyses
are summarized in Table 2.Table 2
Analysis of VH and VL gene usage in the selected Fab clones
Clone VH
family
VH
segment
Differences
from germline
(nucleotides,
amino acids)a
HCDR3
HA1 VH4 DP79 (18, 13) GGNDYGDHQTGSFYY
HA6 VH3 DP47 (24, 16) DRMTSKVWDYGMDV
HA9 VH4 DP71 (14, 6) FSDYYVRDYYGSGTQR
HA12 VH4 DP63 (24, 15) SSSFREFDVRRGAFDI
a Nucleotide and amino acid differences in V-gene segment, excluding CDR3. Th
cam.ac.uk/DNAPLOT.php).Conversion of HAV-specific Fabs to whole IgG
For precise characterization of the antigen-binding nature
of the selected antibody clones, the four different Fabs were
converted to whole IgG (g1, n) molecules and expressed in
DHFR-deficient CHO cells, as described in Materials and
methods. For the large-scale production of the antibodies,
stable cell lines expressing high levels of antibody (10–20
Ag/ml) were established by gene amplification using step-
wise MTX selection and cultured in serum-free medium.
Each MAb was purified from the culture supernatant by
affinity chromatography on a Protein G column. The purity
and integrity of the purified antibodies were confirmed by
SDS-PAGE analysis, which showed more than 95% purity
of IgGs (data not shown). The purified antibodies were used
for further studies.
Antigen-binding activity of HAV-specific MAbs
The antigen-binding activity of the purified MAbs was
measured by an indirect ELISA. All four MAbs (HA1,
HA6, HA9, and HA12) bound to HAV in a concentration-
dependent manner and their affinities for HAV appeared to
be different (Fig. 3). HA6 showed the highest reactivity,VL
family
VL
segment
Differences
from germline
(nucleotides,
amino acids)a
LCDR3
GMDA VK1 DPK9 (2, 0) QQSFSTPYT
VK1 DPK9 (0, 0) QQSYSTTWT
YGLDV VK1 DPK9 (5, 3) QQSYSTPYT
VK1 DPK9 (19, 10) QQSYTTMWT
e nucleotide sequences were analyzed using V-BASE (http://www.mrc-cpe.
Fig. 3. HAV-binding activities of purified human MAbs, HA1 (o), HA6
(5), HA9 (5), and HA12 (w ). Dilutions of the purified antibodies were
added to microtiter wells coated with HAV (200 ng/well). Bound antibodies
were detected by HRP-conjugated goat antihuman IgG (Fc-specific)
antibody.
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ities of HA9 and HA1 ranked lower than that of HA6 in that
order.
Virus neutralization by HAV-specific MAbs
The four MAbs were characterized for HAV neutraliza-
tion by a radioimmunofocus inhibition assay (RIFIA). HAVFig. 4. Radioimmunofocus inhibition assay for virus neutralization by anti-HAV M
only without addition of antibody. The final concentration of antibody in the vir
specific) used as negative control. The HAV plaques formed were detected with a
mouse IgG as a secondary antibody.particles were mixed with serial dilutions of each MAb and
inoculated onto confluent BS-C-1 cell monolayer. After 2
weeks, the foci of infected cells were detected by autoradi-
ography. Fig. 4 shows the results of RIFIA using each MAb.
While irrelevant antibody (CS13, anti-HBsAg MAb) did not
block HAV infection, all four MAbs showed neutralizing
activity against HAV. HA6 completely protected the HAV
infection at a concentration of 50 Ag/ml and reduced the
number of foci by 80% at a concentration of 0.5 Ag/ml. The
neutralizing activities of the four MAbs were positively
correlated with their affinities to HAV.
Characterization of the neutralization epitopes
To test whether the human MAbs recognize the single,
immunodominant neutralization site or not, competition
binding experiments were carried out using the human
MAbs and HAV-neutralizing murine MAbs, K34C8, 7E7
and B5B3 that were known to bind to the immunodominant
neutralization site and were categorized into groups A, D,
and E, respectively, as described in the Introduction (Ping
and Lemon, 1992). As shown in Fig. 5, all four human
MAbs efficiently competed with K34C8, 7E7, and B5B3 in
HAV binding. The efficiency of the inhibition was positive-
ly correlated with the affinity of the human MAbs. The data
suggest that the human MAbs recognize the immunodomi-
nant neutralization site on the HAV capsid.
To investigate whether the four MAbs recognize over-
lapping epitopes or not, cross-competition binding experi-
ments using a biotin-labeled antibody and unlabeled
antibodies were performed (Fig. 6). When the biotin-labeledAbs. The ‘‘virus control’’ represents the result obtained by infection of virus
us-antibody mixture is indicated. CS13 is an irrelevant antibody (HBsAg-
murine anti-HAV MAb, 7E7 as a primary antibody, and 125I-labeled anti-
Fig. 5. Competitive binding assays with murine HAV-neutralizing MAb,
B5B3 (A), 7E7 (B), or K34C8 (C). B5B3, 7E7, or K34C8 antibody was
incubated with HAV (200 ng/well) coated in the microtiter wells in the
presence of dilutions of competing human MAbs, HA1 (o), HA6 (5), HA9
(5), or HA12 (w ). Bound murine antibody was detected by HRP-
conjugated goat anti-mouse IgG (Fc-specific) antibody (Pierce). One
hundred percent binding corresponds to the value of absorbance obtained in
the absence of competing antibody.
Fig. 6. Competitive ELISA. Biotin-labeled HA9 (A), HA12 (B), or HA1
(C) MAb was incubated with HAV (200 ng/well) coated in the microtiter
wells in the presence of serially diluted unlabeled competing antibodies,
HA1 (o), HA6 (5), HA9 (5), or HA12 (w ). Bound biotin-labeled
antibody was detected by Streptavidin–HRP (Pierce). One hundred percent
binding corresponds to the value of absorbance obtained in the absence of
competing antibody.
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Table 3
Competitive inhibition of polyclonal human convalescent antibody binding
to HM-175 virus by monoclonal antibodies, alone or in combination
Competing
antibodiesa
Inhibition of radiolabeled convalescent
human antibodyb
JC-PcAb WL-6-PcAb
PBS 1526 (0%) 1240 (0%)
HA6 (5 Ag/ml) 778 (49%) 582 (53%)
HA9 (5 Ag/ml) 610 (60%) 558 (55%)
HA6 + HA9
(10 Ag/ml)
107 (93%) 37 (97%)
JC-PcAb 15 (99%) 99 (92%)
WL-6-PcAb 76 (95%) 53 (96%)
a JC-PcAb or WL-6-PcAb was added at dilutions yielding maximum
inhibition in antibody competition immunoassays.
b Results are given as the mean of counts per minute (cpm) in replicate
microtiter plate wells ( background cpm), with the percentage of
inhibition of binding within parentheses.
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beled antibodies, all four unlabeled antibodies inhibited the
binding of the labeled HA9, albeit to different extents (Fig.
6A). The binding of labeled HA9 was inhibited more
efficiently by unlabeled HA6 than by unlabeled HA9 itself,
although HA1 and HA12 were less efficient than unlabeled
HA9 in inhibiting the binding. The concentration of HA6,
HA9, HA1, or HA12 required for 50% inhibition of the
binding of labeled HA9 was estimated to be 0.7, 2, 5, or 40
Ag/ml, respectively. The efficiency of the inhibition was
positively correlated with the affinity of the MAbs. The data
suggest that the epitopes of the MAbs are overlapped.
When biotin-labeled HA12 was used in this competitive
binding assay, minimal inhibition by HA1 was observed,
whereas HA12 was very efficiently inhibited by HA6 or
HA9 (Fig. 6B). Considering that the affinity of HA1 is
higher than that of HA12 (Fig. 3), it is evident that HA1 and
HA12 recognize distinct epitopes. This is consistent with the
result of the competition binding assay using biotin-labeled
HA1, shown in Fig. 6C. The binding of biotin-labeled HA1
was not inhibited by HA12, although it was inhibited more
efficiently by HA6 or HA9 than by unlabeled HA1 itself.
Taken together, it may be reasonable to conclude that (1) the
epitopes of the four MAbs are near to each other, (2) HA1
and HA12 recognize distinct epitopes, and (3) HA6 and
HA9 recognize extensively overlapping epitopes which
overlap with that of HA1 or HA12 (Fig. 7).
To determine if these neutralization epitopes represent the
majority of antigenic sites on HAV that elicit neutralizing
antibodies during natural infection, we used a competition
radioimmunoassay between the Mabs and two polyclonal
human anti-HAV IgGs (PcAbs) described previously (Sta-
pleton and Lemon, 1987; Stapleton et al., 1991). In this
assay, HA6 and HA9 inhibited the binding of HM-175 HAVFig. 7. The predicted topography of the epitopes recognized by four human
MAbs HA1, HA6, HA9, and HA12 within the immunodominant
neutralization site.to PcAb by 49% to 60% individually (Table 3). However,
when both HA6 and HA9 were added together, HAV
binding to PcAb was inhibited by more than 90%, indicating
that the epitopes eliciting these antibodies represent those of
most antibodies elicited during natural infection.
Most neutralizing murine MAbs to HAV, including
B5B3, recognize both 70S and 14S subviral particles,
whereas K34C8 recognize 70S particles, but not 14S par-
ticles (Stapleton et al., 1993). The epitope specificity of the
human MAbs was further characterized by measuring their
reactivity to the 14S and 70S subviral particles that had been
prepared as described previously (Stapleton et al., 1993;
Winokur et al., 1991). The 14S or 70S particles captured by
each of the human MAbs were detected using 125I-labeled
anti-HAV IgG. Anti-HAV human serum and anti-HIV
gp120 MAb were used as a positive and a negative control,
respectively. As shown in Fig. 8, the human MAbs were
reactive to both 70S and 14S particles. The binding strengthFig. 8. Reactivity of anti-HAV human MAbs to purified 70S and 14S
subviral particles. The subviral particles were captured by human MAb
coated on microtiter wells and detected by 125I-labeled anti-HAV IgG. The
‘‘polyclonal’’ results represent HAV-immune human serum as the positive
control, and the ‘‘anti-HIV’’ represents an anti-HIV gp120 MAb, which
served as the negative control.
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correlated with their antigen-binding affinity.Discussion
A diverse set of human MAbs can be obtained efficiently
from a phage antibody library generated from immune
donors. In this study, we isolated four different HAV-
neutralizing human MAbs (HA1, HA6, HA9, and HA12)
by phage display of the antibody library generated from the
PBLs of HAV-immune donors recovered from hepatitis A.
The four MAbs have highly homologous VL sequences.
However, they have the markedly different VH sequences
including CDRs (Table 2), suggesting that they may recog-
nize different epitopes with differential affinity. Indeed, the
four MAbs demonstrated differential HAV-binding capabil-
ity and fine epitope specificity (Figs. 3,5–7). HA6 and HA9
had the highest and second highest affinity, respectively, and
represented 59% and 32% of the selected HAV-specific
clones, respectively. HA12 antibody had the lowest affinity
and represented only 5% of the clones (Table 1), reflecting
that the panning was efficient in selecting the clones of high
affinity.
All four human MAbs showed HAV-neutralizing activity
(Fig. 4). In competitive binding assays, they completely
blocked the binding of HAV-neutralizing murine MAbs,
K34C8, 7E7, and B5B3 (Fig. 5), suggesting that the
epitopes of the human MAbs are part of the single immu-
nodominant neutralization site and may extensively overlap
with those of the murine MAbs. Characterization of their
fine epitope specificity by cross-competition binding assays
suggested that their epitopes are closely spaced and overlap
with each other, although HA1 and HA12 recognized
distinct epitopes (Figs. 6 and 7). In addition, HA6 and
HA9 inhibited the HAV binding of polyclonal human anti-
HAV sera by more than 90% (Table 3), suggesting that the
epitopes of these antibodies represent those of most neu-
tralizing antibodies elicited during natural infection.
All the human MAbs bound to both 70S and 14S
particles (Fig. 8). Previous findings demonstrated that most
MAbs recognized both 70S and 14S subviral particles,
whereas K34C8 recognized only 70S particles. When 14S
particles were concentrated, 70S assembly was observed,
and the K34C8 epitope was formed (Stapleton et al., 1993).
Characterization of neutralization escape mutants found that
the B5B3 and K34C8 epitopes clustered within a single
immunodominant neutralization site; however, the epitopes
were distinct and did not compete for binding with each
other in binding assays (Stapleton and Lemon, 1987). Thus,
our results suggest that the epitopes recognized by the
human MAbs are clustered within the single immunodomi-
nant neutralization site on the HAV capsid, and extensively
overlap with those of B5B3 and K34C8. The fine epitope
specificity of the human MAbs is different from that of the
chimpanzee MAbs, whose epitopes were overlapping withK34C8, but not with B5B3 (Schofield et al., 2002). There-
fore, there may be subtle differences in HAV antigen
processing among murine, chimpanzee, and human systems.
In summary, we isolated four different neutralizing
human MAbs to HAV by phage display. The human MAbs
recognized the immunodominant neutralization site on the
HAV capsid with differential antigen-binding affinities. The
human MAbs (HA6 and HA9) with highest affinity may be
useful in the immunoprophylaxis of HAV infection.Materials and methods
Construction of phage antibody library from immunized
donors
About 200 ml of blood was collected from seven donors
who were hospitalized and recovered from HAV infection in
Korea, and PBLs were purified on a Ficoll gradient (Amer-
sham Pharmacia Biotech., Piscataway, NJ). Total RNA was
extracted from the purified PBLs using RNAzol B (Tel-Test,
Inc., Friendswood, TX), and first-strand cDNAs were syn-
thesized using SUPERSCRIPT II (Life Technologies, Rock-
ville, MA) with 3V-primers specific for the Fd region of
human g1 heavy chain and the constant region of human n
light chain. The cDNAs were then amplified by PCR using
rTaq polymerase (Takara, Shiga, Japan) and 5V-family spe-
cific primers for human light and heavy chain variable
regions, as described previously (Burton et al., 1991; Persson
et al., 1991) in combination with the 3V-primers. After gel-
purifying 660-bp PCR products, the DNA was reamplified
with extension primers to increase the efficiency of restric-
tion enzyme digestion and subsequent library construction.
The final PCR products encoding the repertoire of light
chains were digested with SacI and XbaI (Boehringer Man-
nheim, Indianapolis, IN) and ligated into the SacI–XbaI sites
of pComb3H, a variant of pComb3 (Barbas et al., 1991),
which was then electroporated into E. coli XL1-Blue cells.
Subsequently, the final PCR products encoding the library of
the Fd regions of the heavy chain were digested with SpeI
and XhoI (Boehringer Mannheim) and ligated into the SpeI–
XhoI sites of the recombinant pComb3H containing the light
chain cDNA library, which was then electroporated into E.
coli TG1 cells. The phages displaying Fab library were
rescued by the infection of the transformed cells with
VCSM13 helper phage (Stratagene, La Jolla, CA). To
examine the authenticity of the library, 20 clones were
picked at random and analyzed; more than 95% of clones
were shown to possess both light and heavy chain inserts.
Biopanning
The wells of a microtiter plate (Nunc, Naperville, IL)
were coated with 200 ng of HAV (Biogenesis, Kingston,
NH) at 4 jC overnight. The wells were washed twice with
PBS and blocked by 4% skim milk in PBS at 37 jC for 2 h.
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phage (about 1011 colony forming units) in PBS with 2%
skim milk was added to each well and incubated at 37 jC
for 2 h. The unbound phages were discarded and the wells
were washed five times with 0.05% Tween 20 in PBS
(PBST) and twice with distilled water. Bound phages were
eluted with 0.1 M glycine–HCl (pH 2.2) and neutralized
with 2 M Tris base. The eluted phages were amplified by
infecting TG1 cells followed by their super-infection with
the helper phage (Marks et al., 1991). The amplified phages
were then subjected to another round of panning. Four
rounds of panning were carried out and the stringency of
selection was increased with each round with an increase in
the number of washes.
Preparation of soluble Fab
To screen and characterize anti-HAV clones, soluble Fab
was prepared as described previously (Burton et al., 1991).
Briefly, the plasmid DNA isolated after the final round of
panning was digested with SpeI and NheI (Boehringer
Mannheim) to remove DNA segment containing gene III,
recircularized by self-ligation and then electroporated into
E. coli TG1 cells. Twenty-four colonies were randomly
selected, cultured in 5 ml SB with 100 Ag/ml ampicillin,
and induced for Fab expression using 1 mM isopropyl h-D-
thiogalactopyranoside. The culture supernatant of each
clone was used as a source of soluble Fab.
Sequence analysis of anti-HAV Fabs
The restriction enzyme BstNI cuts frequently in the
human g1 heavy chain (Marks et al., 1991). BstNI restriction
digestion was used to screen for different Fab clones among
those isolated. One microgram of the plasmid DNA was
digested with 1U of BstNI (New England BioLabs, Beverly,
MA) at 60 jC for 2 h and analyzed by electrophoresis on a
3% agarose gel. Next, the clones showing different restric-
tion maps were subjected to DNA sequencing using T7
Sequenase version 2.0 DNA sequencing kit (Amersham
Pharmacia Biotech.). The nucleotide sequences determined
were submitted to V-BASE (http://www.mrc-cpe.cam.ac.uk/
DNAPLOT.php) for sequence analysis.
Production of anti-HAV human IgGs
The VH and VL sequences in the Fab expression plas-
mids were amplified by PCR and combined with the leader
sequences of Ig heavy and light chains, respectively, by
recombinant PCR. The VH and VL with leader sequences
were sequentially subcloned into the EcoRI–ApaI and
HindIII–BsiWI sites, respectively, of an antibody expression
cassette (pdCMV-dhfrC) containing the human g1 and n
constant regions, constructed in our laboratory by modifying
a mammalian expression vector pKC-dhfr-huS (Ryu et al.,
1996). The resulting expression plasmid was introduced intodihydrofolate reductase (DHFR)-deficient Chinese hamster
ovary cell line (DG44) using lipofectamin (Life Technolo-
gies) according to the protocol suggested by the supplier.
Subsequently, dhfr+/neor clones were selected in a-MEM
(Life Technologies) containing 10% dialyzed FBS (Life
Technologies) and G418 (550 Ag/ml, Life Technologies).
Drug-resistant clones were subjected to stepwise dhfr-me-
diated gene amplification in the presence of increasing level
of methotrexate (MTX), as described previously (Kim et al.,
1998). The concentration of antibody in the culture super-
natant was determined by ELISA. For purification of IgG,
the MTX-selected cell lines were grown in serum-free media
(CHO-SFM II, Life Technologies), and the culture superna-
tant was subjected to affinity chromatography on Protein G-
Sepharose column (Amersham Pharmacia Biotech.) as de-
scribed previously (Ryu et al., 1996). For the quantification
of the purified antibody, the optical density of 1.43 at 280
nm was taken for the protein concentration of 1 mg/ml.
ELISA
Microtiter wells were coated with antigens or antibodies
diluted in 50 mM sodium carbonate buffer (pH 9.6) at 4 jC
overnight, and blocked with 2% BSA or skim milk in PBS.
The plates were washed four times in PBST between each
step. All the incubations were carried out at 37 jC for 1–2
h. Color was developed with 2V,2V-Azino-Bis (3-Ethylbenz-
thiazoline-6-s-Sulphonic Acid) diammonium salt (Sigma,
St. Louis, Mo.), and the absorbance of developed color
was measured at 405 nm using a microtiter reader (Emax,
Molecular Devices, Sunnyvale, CA).
Radioimmunofocus inhibition assay
The neutralizing activity of anti-HAV MAbs was deter-
mined in duplicate, by a radioimmunofocus inhibition assay,
as described previously (Funkhouser et al., 1994; Lemon
and Binn, 1983). Briefly, African green monkey kidney
(BS-C-1) cells were plated in 6-well plates with Thermanox
round 25-mm coverslips (Nunc) affixed to the bottom of
each well with 1% agarose. Dilutions of antibody were
mixed with HM-175/7 HAV (500 radioimmunofocus-form-
ing units) which had been prepared from pHAV/7 as
described previously (Cohen et al., 1987). The mixture
was incubated at 35 jC for 2 h. The confluent cell
monolayer was inoculated with the virus–antibody mixture
and overlaid with agarose. After 2 weeks, the cell mono-
layer was fixed with acetone, and the HAV plaques formed
were detected with an anti-HAV MAb, 7E7 (Mediagnost) as
a primary antibody and 125I-labeled anti-mouse IgG (Amer-
sham Pharmacia Biotech.) as a secondary antibody.
Reactivity of anti-HAV MAbs to HAV subviral particles
The ability of each MAb to bind recombinant 14S and
70S subviral particles was determined as described previ-
S.J. Kim et al. / Virology 318 (2004) 598–607606ously (Stapleton et al., 1993; Winokur et al., 1991).
Briefly, TK-143 cells were infected with recombinant
vaccinia virus expressing the entire HAV open reading
frame (rV-HAV), and the recombinant 14S and 70S par-
ticles contained in the cell lysate were separated on 7.5–
45% sucrose gradients. Microtiter wells were coated with
each antibody, and 14S or 70S particles were added to the
wells. Captured HAV subviral particles were detected using
125I-labeled polyclonal anti-HAV IgG (Stapleton et al.,
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